1.
Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma
by Garcia, Jorge A.
BJU International, January 2012, Vol.109(1), pp.63-69

2.
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
by Garcia, Jorge A
BJU international, February 2011, Vol.107(4), pp.562-570
